Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound medicinal composition containing acetylcholinesterase inhibitor and metformin

A technology of acetylcholinesterase and metformin, applied in the field of medicine, can solve the problems of inability to improve AD nerve cell function, deterioration of cognitive impairment, brain nerve cell death, etc.

Active Publication Date: 2017-11-17
南京千手共创生物科技有限公司 +1
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] With the development of AD disease, brain nerve cells die and lose the connection between nerve cells, leading to the deterioration of cognitive impairment, but the existing drugs can not improve the function of AD nerve cells, only limited short-term improvement or stable symptoms

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound medicinal composition containing acetylcholinesterase inhibitor and metformin
  • Compound medicinal composition containing acetylcholinesterase inhibitor and metformin
  • Compound medicinal composition containing acetylcholinesterase inhibitor and metformin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Donepezil Hydrochloride and Metformin Hydrochloride Compound Tablets

[0036] Prescription: Ordinary Tablets (Based on 1000 Tablets)

[0037] components

Dosage

Donepezil Hydrochloride

5g

Metformin Hydrochloride

500g

microcrystalline cellulose

45g

Croscarmellose Sodium

10g

Magnesium stearate

4g

2% hypromellose (solid weight)

6g

[0038] Preparation:

[0039] (1) Pass donepezil hydrochloride, metformin hydrochloride, and microcrystalline cellulose through an 80-mesh sieve respectively, and after uniformly mixing by an equal-volume increasing method, premix with 2% hypromellose and wet granulate;

[0040] (2) drying and sizing the granules prepared by wet granulation to obtain dry granules;

[0041] (3) blending dry granules with croscarmellose sodium and magnesium stearate to obtain blended granules;

[0042] (4) Compressing the blended granules into tablets to obtain tablets.

Embodiment 2

[0044] Donepezil Hydrochloride and Metformin Hydrochloride Bilayer Tablets

[0045] Prescription: double layer tablet (according to 1000 tablets)

[0046]

[0047] Preparation:

[0048] (1) Pass donepezil hydrochloride, microcrystalline cellulose, and starch through an 80-mesh sieve respectively, and after mixing uniformly by the method of equal increments, premix with 2% hypromellose and perform wet granulation;

[0049] (2) Metformin hydrochloride and microcrystalline cellulose were respectively passed through an 80-mesh sieve, mixed evenly by an equal-volume increasing method, premixed with 2% hypromellose and wet-granulated;

[0050] (3) drying and sizing the A-layer and B-layer granules prepared by wet granulation, respectively, to obtain the dried granules of the A-layer and B-layer;

[0051] (4) The dry granules of A layer and B layer are blended with croscarmellose sodium and magnesium stearate respectively to obtain the blended granules of A layer and B layer;

...

Embodiment 3

[0054] Donepezil Hydrochloride and Metformin Hydrochloride Capsules

[0055] Prescription: Capsules (according to 1000 capsules)

[0056] components

Dosage

Donepezil Hydrochloride

5g

Metformin Hydrochloride

250g

microcrystalline cellulose

30g

Magnesium stearate

10g

2% hypromellose (solid weight)

10g

[0057] Preparation:

[0058] (1) Pass donepezil hydrochloride, metformin hydrochloride and microcrystalline cellulose through an 80-mesh sieve respectively, mix uniformly by the method of equal volume increment, premix with 2% hypromellose and wet granulate.

[0059] (2) drying and sizing the granules prepared by wet granulation to obtain dry granules;

[0060] (3) dry granules are mixed with magnesium stearate to obtain mixed granules;

[0061] (4) Fill the blended granules into capsules with a capsule filling machine to obtain capsules.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medicine, and specifically relates to a compound medicinal composition with acetylcholinesterase inhibitors such as donepezil, galantamine or huperzine A and metformin as active ingredients, a preparation method thereof and a therapeutic use thereof. Pharmacodynamic tests show that the compound pharmaceutical composition of the present invention can be used for the prevention and treatment of Alzheimer's dementia, and the combined use of the compound medicine has a synergistic effect in curative effect.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a compound medicinal combination with acetylcholinesterase inhibitors such as Donepezil, Galanthamine or Huperzine A and Metformin as active ingredients substances, their preparation and their therapeutic uses. Background technique [0002] In 2013, there were 44 million Alzheimer's (Alzheimer's disease, AD) patients worldwide, and it is estimated that there will be 76 million patients by 2030. The current global annual cost of AD treatment is estimated at $315 billion. In 2013, the total number of AD patients in my country was about 9 million, ranking first in the world. By the end of 2013, there were 202 million people aged 60 and above, accounting for 14.9% of the total population. The prevalence of AD in the population over 60 years old is estimated to be 3%, and the prevalence of AD in the population over 85 years old is estimated to be 40%. The discovery of effective pr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/06A61K31/445A61K31/4748A61K31/55A61P25/28A61K31/155
Inventor 贡岳松徐云根
Owner 南京千手共创生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com